Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKinsey
Boehringer Ingelheim
Colorcon
Harvard Business School

Last Updated: February 9, 2023

Lilly Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Lilly
International Patents:45
US Patents:2
Tradenames:87
Ingredients:82
NDAs:108

Drugs and US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly NEBCIN tobramycin sulfate INJECTABLE;INJECTION 050477-005 Approved Prior to Jan 1, 1982 DISCN Yes No See Plans and Pricing See Plans and Pricing
Lilly DICUMAROL dicumarol CAPSULE;ORAL 005509-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Lilly NEOTRIZINE trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) TABLET;ORAL 006317-011 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Lilly DECABID indecainide hydrochloride TABLET, EXTENDED RELEASE;ORAL 019693-001 Dec 29, 1989 DISCN No No See Plans and Pricing See Plans and Pricing
Lilly TAZIDIME IN PLASTIC CONTAINER ceftazidime INJECTABLE;INJECTION 062739-001 Jul 10, 1986 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 5,710,285 See Plans and Pricing
Lilly DECABID indecainide hydrochloride TABLET, EXTENDED RELEASE;ORAL 019693-002 Dec 29, 1989 4,452,745 See Plans and Pricing
Lilly PROZAC fluoxetine hydrochloride TABLET;ORAL 020974-001 Mar 9, 1999 4,626,549*PED See Plans and Pricing
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 5,843,984 See Plans and Pricing
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-002 Apr 6, 2000 5,817,656 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg ➤ Subscribe 2005-01-10
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2005-11-01
➤ Subscribe For Injection 2 g/vial ➤ Subscribe 2007-08-24
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2008-02-04
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe 2016-10-06
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2008-10-14
➤ Subscribe Delayed-release Capsules 20 mg, 30 mg and 60 mg ➤ Subscribe 2008-08-04
➤ Subscribe Capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg ➤ Subscribe 2007-05-29
➤ Subscribe Capsules 3 mg/25 mg ➤ Subscribe 2008-05-08
➤ Subscribe For Injection 1g/vial ➤ Subscribe 2005-11-14
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe 2008-07-01
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe 2012-06-27
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe 2015-07-27
➤ Subscribe Tablets 5 mg, 10 mg and 20 mg ➤ Subscribe 2007-11-21
➤ Subscribe Delayed-release Capsules 40 mg ➤ Subscribe 2012-05-10

Supplementary Protection Certificates for Lilly Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1441735 SPC/GB08/020 United Kingdom See Plans and Pricing PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
0454436 SPC/GB96/058 United Kingdom See Plans and Pricing PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
0720599 300689 Netherlands See Plans and Pricing PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
1718641 2012/008 Ireland See Plans and Pricing PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
1499331 13C0055 France See Plans and Pricing PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
AstraZeneca
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.